Without competent researchers, innovation processes in European medicines development will not be sustainable, say Klaus Wassermann and Christa Janko, EMTRAIN
Following Turing Pharmaceuticals’ famous 5,000% price hike on critical drug Daraprim, Canadian pharma group Valeant has followed up with a similarly incredulous move
Dr David Roblin, chief operating officer and director of scientific translation at the Francis Crick Institute in London, talks to EPM about the Institute’s recent partnership with GSK that will address a number of disease areas
